Unknown

Dataset Information

0

Highly versatile cancer photoimmunotherapy using photosensitizer-conjugated avidin and biotin-conjugated targeting antibodies.


ABSTRACT: Background:Photoimmunotherapy (PIT) employing antibody-photosensitizer conjugates is a promising treatment for cancer. However, the fixed antigen specificity severely limits the efficacy and the applicability. Here we describe a universal strategy for PIT of cancer by using a near-infrared (NIR) photosensitizer IRDye700DX-conjugated NeutrAvidin, designated as AvIR, together with various biotinylated antibodies (BioAbs) for cellular targeting. Methods:Cytotoxicity of AvIR-mediated PIT was evaluated by fluorescence imaging and cell viability assay. Phototoxic effect on tumorigenicity was assessed by tumorsphere-formation assay and Matrigel invasion assay. Cancer stem cell-like side-population (SP) cells were identified by flow cytometry. Results:CHO cells stably expressing carcinoembryonic antigen or EpCAM were pre-labeled with each BioAb for the corresponding antigen, followed by AvIR administration. NIR light irradiation specifically killed the targeted cells, but not off-targets, demonstrating that the AvIR-mediated PIT does work as expected. CSC-like subpopulation of MCF-7 cells (CD24low/CD44high) and SP of HuH-7 cells (CD133+/EpCAM+) were effectively targeted and photokilled by AvIR-PIT with anti-CD44 BioAb or anti-CD133/anti-EpCAM BioAbs, respectively. As results, the neoplastic features of the cell lines were sufficiently suppressed. Cancer-associated fibroblast (CAF)-targeted AvIR-PIT by using anti-fibroblast activation protein BioAb showed an abolishment of CAF-enhanced clonogenicity of MCF-7 cells. Conclusions:Collectively, our results demonstrate that AvIR-mediated PIT can greatly broaden the applicable range of target specificity, with feasibility of efficacious and integrative control of CSC and its microenvironment.

SUBMITTER: Shirasu N 

PROVIDER: S-EPMC6858743 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Highly versatile cancer photoimmunotherapy using photosensitizer-conjugated avidin and biotin-conjugated targeting antibodies.

Shirasu Naoto N   Shibaguchi Hirotomo H   Yamada Hiromi H   Kuroki Masahide M   Yasunaga Shin'ichiro S  

Cancer cell international 20191115


<h4>Background</h4>Photoimmunotherapy (PIT) employing antibody-photosensitizer conjugates is a promising treatment for cancer. However, the fixed antigen specificity severely limits the efficacy and the applicability. Here we describe a universal strategy for PIT of cancer by using a near-infrared (NIR) photosensitizer IRDye700DX-conjugated NeutrAvidin, designated as AvIR, together with various biotinylated antibodies (BioAbs) for cellular targeting.<h4>Methods</h4>Cytotoxicity of AvIR-mediated  ...[more]

Similar Datasets

| S-EPMC7730620 | biostudies-literature
| S-EPMC7711042 | biostudies-literature
| S-EPMC3383089 | biostudies-literature
| S-EPMC2834590 | biostudies-literature
| S-EPMC6484861 | biostudies-literature
| S-EPMC4004687 | biostudies-literature
| S-EPMC6017280 | biostudies-literature
| S-EPMC4632738 | biostudies-literature
| S-EPMC7210587 | biostudies-literature
| S-EPMC6761202 | biostudies-literature